Latigo Biotherapeutics (NASDAQ:LTGO) Rating Increased to Strong-Buy at The Goldman Sachs Group

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by stock analysts at The Goldman Sachs Group to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen raised Latigo Biotherapeutics to a “hold” rating in a research note on Saturday, August 15th. Guggenheim began coverage on shares of Latigo Biotherapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 price target on the stock. Leerink Partners assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Latigo Biotherapeutics in a research note on Tuesday. They set a “buy” rating and a $50.00 price objective for the company. Four research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Strong Buy” and a consensus target price of $52.25.

Latigo Biotherapeutics Stock Up 1.1%

LTGO stock opened at $22.26 on Tuesday. Latigo Biotherapeutics has a twelve month low of $17.22 and a twelve month high of $25.93.

Insiders Place Their Bets

In other news, Director James B. Tananbaum acquired 140,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the acquisition, the director directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. The trade was a 7.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the insider owned 2,008,024 shares of the company’s stock, valued at $36,144,432. The trade was a 7.49% increase in their position. The disclosure for this purchase is available in the SEC filing.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.